CTLA4 and metastatic melanoma: Recently, immune checkpoint inhibitors, including the anti-CTLA-4 monoclonal antibody ipilimumab and the anti-PD monoclonal antibody MDX-1106, have shown single agent efficacy in patients with metastatic melanoma [75, 76].